CCP
ATRS

Clarkston Capital Partners’s Antares Pharma, Inc. ATRS Stock Holding History

Clarkston Capital Partners’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-21,760
Closed -$88K – 116
2013
Q3 		$88K Hold
21,760
– – 0.04% 95
2013
Q2 		$91K Buy
+21,760
New +$84.1K 0.05% 95

Other funds holding ATRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Clarkston Capital Partners's ATRS Position: Q4 2013 in Review

Clarkston Capital Partners sold out of Antares Pharma, Inc. (ATRS) in Q4 2013, closing a stake of 21,760 shares — an estimated $88K sold.

Clarkston Capital Partners first reported a position in ATRS in Q2 2013 and held it in 2 quarters. The position peaked at $91K in Q2 2013. 89 funds tracked by Wall St. Rank hold ATRS as of Q4 2013.

  • Clarkston Capital Partners reported no remaining Antares Pharma, Inc. position as of Q4 2013 after selling out during the quarter.
  • Clarkston Capital Partners sold 21,760 Antares Pharma, Inc. shares in Q4 2013, an estimated $88K.
  • Clarkston Capital Partners first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 2 quarters.
  • Clarkston Capital Partners's Antares Pharma, Inc. position peaked at $91K in Q2 2013.
  • 89 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2013.

Based on Clarkston Capital Partners's 13F filing for Q4 2013, filed 29 Jan 2014.